Actively Recruiting
Study to Evaluate the Safety and Effectiveness of NBI-1065845 as an Additional Treatment for Adults With Major Depressive Disorder
Led by Neurocrine Biosciences · Updated on 2026-08-10
200
Participants Needed
35
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of NBI-1065845 compared with a placebo as an additional treatment for adults with Major Depressive Disorder MDD. This trial focuses on improving symptoms of depression in participants who have not responded well to standard oral antidepressant treatments during their current episode. The study is designed as a randomized, double-blind, placebo-controlled trial primarily evaluating treatment outcomes in this population. Participants will receive either NBI-1065845 tablets or placebo tablets that look identical. Both treatments are taken orally once a day alongside their current oral antidepressants, which participants must continue at the same dose and frequency throughout the study. The main treatment period lasts 56 days, during which researchers will monitor changes in depression symptoms and disability. Throughout the study, participants will undergo assessments including the Montgomery-sberg Depression Rating Scale MADRS, Sheehan Disability Scale SDS, and Clinical Global Impression-Severity Scale CGI-S at the start and end of the 56-day period. Researchers will evaluate changes in these scores to measure symptom improvement. The trial includes close monitoring to ensure participant safety and adherence, with total participation lasting about two months.
CONDITIONS
Brief Title
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Research Team
N
Neurocrine Medical Information Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here